Journal of Clinical Oncology, Vol 11, 2211-2217, Copyright © 1993 by American Society of Clinical Oncology

ARTICLES

Relation of tumor-cell ploidy to survival in children with medulloblastoma

AJ Gajjar, RL Heideman, EC Douglass, LE Kun, EH Kovnar, RA Sanford, DL Fairclough, D Ayers and AT Look
Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105.

PURPOSE: To assess the value of tumor-cell ploidy as a predictor of survival in medulloblastoma. PATIENTS AND METHODS: Ploidy determinations were based on the flow-cytometric analysis of cellular DNA content in fresh tumor specimens taken from 34 consecutively treated children with newly diagnosed medulloblastoma. Patients were assigned a high or low risk of failure depending on tumor size and invasiveness, and the presence or absence of metastatic disease. Treatment consisted of radiotherapy, with or without chemotherapy, according to institutional or cooperative group protocols. RESULTS: Univariate analysis of candidate prognostic factors showed that only tumor-cell ploidy and clinical risk group had a statistically significant influence on survival. Patients with hyperdiploid stem lines (n = 9) had significantly longer survival times (P = .04) than did those with diploid lines (n = 20). The estimated 5-year survival probabilities (+/- SE) for these two subgroups were 89% +/- 11% and 48% +/- 13%, respectively. Although clinical risk status (high v low) showed essentially the same predictive strength as ploidy, the two features identified largely nonoverlapping subgroups. Thus, within the clinical high-risk group, it was possible to distinguish hyperdiploid patients whose 5-year survival rate (83% +/- 15%) was comparable to that of patients with localized, low-risk tumors. CONCLUSION: This prospective study indicates that both ploidy and clinical risk group are important prognostic factors in medulloblastoma. Their combined use at diagnosis would distinguish patients who require more aggressive therapeutic intervention (diploid, clinical high-risk group) from those who could be expected to benefit most from standard treatment.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. M. Lamont, C. S. McManamy, A. D. Pearson, S. C. Clifford, and D. W. Ellison Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients Clin. Cancer Res., August 15, 2004; 10(16): 5482 - 5493. [Abstract] [Full Text] [PDF]

				P. G. Fisher, P. C. Burger, and C. G. Eberhart Biologic Risk Stratification of Medulloblastoma: The Real Time Is Now J. Clin. Oncol., March 15, 2004; 22(6): 971 - 974. [Full Text] [PDF]

				R. J. Packer, P. Cogen, G. Vezina, and L. B. Rorke Medulloblastoma: Clinical and biologic aspects Neuro-oncol, July 1, 1999; 1(3): 232 - 250. [Abstract] [PDF]

				R. J. Packer and J. L. Finlay Chemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors Oncologist, December 1, 1996; 1(6): 381 - 393. [Abstract] [Full Text] [PDF]